Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Volatile Organic Compound Signatures as a Predictive and Therapeutic Response Biomarker for Mepolizumab Therapy in Severe Eosinophilic Asthma

NCT04924478 is registered in ClinicalTrials.gov with University Hospital Southampton NHS Foundation Trust as lead sponsor.

NCT NCT04924478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04924478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Volatile Organic Compound Signatures as a Predictive and Therapeutic Response Biomarker for Mepolizumab Therapy in Severe Eosinophilic Asthma
Lead sponsor
University Hospital Southampton NHS Foundation Trust
Phase
Observational
Overall status
Unknown status
Start date
July 31, 2021
Completion date
December 31, 2022
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma; eosinophilic